Who makes BMS-986165 prototype 2?

BMS-986165 prototype 2 is developed by Bristol-Myers Squibb.

What development phase is BMS-986165 prototype 2 in?

BMS-986165 prototype 2 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

BMS-986165 prototype 2

Bristol-Myers Squibb · Phase 1 active Small molecule

At a glance

Generic name	BMS-986165 prototype 2
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants (PHASE1)
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets (PHASE1)
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BMS-986165 prototype 2 CI brief — competitive landscape report
BMS-986165 prototype 2 updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI